Clinical Trials Browser

Uterine Anomalies, Endometriosis, Endometritis, Infertility, Infertility, Female, Leiomyoma, Polycystic Ovary Syndrome, Pregnancy, Ectopic, Salpingitis, Primary Ovarian Insufficiency

NCT05019846 2023-04-18

SPA

Phase 3 Recruiting

310 enrolled

Genitourinary

Prostatic Neoplasms

Clinical Trials

High-Dose Brachytherapy in Treating Patients With Prostate Cancer

VA STARPORT

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer

Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study

THUNDER

Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response

Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer

Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT

PREcoopERA

Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer

SOFT

TEXT

Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland

NePtune

Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

STEEL

DIVINE

First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer

Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer

The COSMYC Trial (COmbined Suppression of MYC)

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate

Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer

CARLHA-2

TriptoSwitch

Triptorelin and Radiation Therapy in Treating Patients Who Have Undergone Surgery for Intermediate-Risk Stage III or Stage IV Prostate Cancer

GREAT

SOLTI-2104

Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer

Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer

FACILE

The Predictive Value of TMPRSS2-ERG Fusion in High Risk Prostate Cancer Patient

PCS IX

Micro RNAs to Predict Response to Androgen Deprivation Therapy

Androgen Deprivation Therapy in Advanced Salivary Gland Cancer

ECHOS

SAVE

DEFINE

LOBSTER

URONCOR 06-24

ProFertil

Effect of GnRH Agonist vs GnRH Antagonist on IVF/ICSI Outcomes in Polycystic Ovary Syndrome Patients.

Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology in Polycystic Ovary Syndrome Patients During IVF/ICSI

Depo-Trigger

CS-EOSP-ICSI

SPA